enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. Cancer immunotherapy - Wikipedia

   en.wikipedia.org/wiki/Cancer_immunotherapy

   Cancer immunotherapy (immuno-oncotherapy) is the stimulation of the immune system to treat cancer, improving the immune system's natural ability to fight the disease. [1] It is an application of the fundamental research of cancer immunology ( immuno-oncology ) and a growing subspecialty of oncology .

3. Immunotherapy - Wikipedia

   en.wikipedia.org/wiki/Immunotherapy

   Immunotherapy or biological therapy is the treatment of disease by activating or suppressing the immune system. Immunotherapies designed to elicit or amplify an immune response are classified as activation immunotherapies, while immunotherapies that reduce or suppress are classified as suppression immunotherapies .

4. Cancer immunology - Wikipedia

   en.wikipedia.org/wiki/Cancer_immunology

   Tumor-associated immune cells in the tumor microenvironment (TME) of breast cancer models. Cancer immunology (immuno-oncology) is an interdisciplinary branch of biology and a sub-discipline of immunology that is concerned with understanding the role of the immune system in the progression and development of cancer; the most well known application is cancer immunotherapy, which utilises the ...

5. Immune-related response criteria - Wikipedia

   en.wikipedia.org/wiki/Immune-Related_Response...

   The immune-related response criteria (irRC) is a set of published rules that define when tumors in cancer patients improve ("respond"), stay the same ("stabilize"), or worsen ("progress") during treatment, where the compound being evaluated is an immuno-oncology drug. Immuno-oncology, part of the broader field of cancer immunotherapy, involves ...

6. PD-1 and PD-L1 inhibitors - Wikipedia

   en.wikipedia.org/wiki/PD-1_and_PD-L1_inhibitors

   Immunotherapy with these immune checkpoint inhibitors appears to shrink tumours in a higher number of patients across a wider range of tumour types and is associated with lower toxicity levels than other immunotherapies, with durable responses. [5] However, de-novo and acquired resistance is still seen in a large proportion of patients. [9]

7. Response evaluation criteria in solid tumors - Wikipedia

   en.wikipedia.org/wiki/Response_Evaluation...

   Immuno-oncology [ edit ] The RECIST criteria present problems for immunotherapies so around 2009 the immune-related response criteria were developed and are used in some immunotherapy clinical trials.